10.11.19
CMAB Biopharma (Suzhou) Inc., a biologics CDMO, and BJ Bioscience, an innovative biopharmaceutical company, have entered a strategic agreement for the development and manufacturing of a Bi-functional Antibody (BJ-005) as the first step in an exclusive collaboration.
CMAB will provide a full range of CMC research and manufacturing services to support the IND application requirements of both China and the U.S. The collaboration will support the clinical development of BJ-005 worldwide by BJ Bioscience and will leverage CMAB's CMC process development and manufacturing platform, R&D team, and product quality system.
"We had ambitious goals and aspirations at the beginning of setting up BJ Bioscience," said Mr. Xiaoyong, JIN, Chairman of BJ Bioscience. "So far, China's biopharmaceutical companies have very few innovative drugs on the market. We believe that BJ Bioscience will develop real innovative biologics in the foreseeable future. The primary goal for our cooperation with CMAB is that we may focus more on the innovative R&D fields that we are good at and leave the CMC part to CMAB because it is its expertise. We believe that our efforts in all respects will open up an era for stronger, win-win cooperation."
"CMAB stood out in our strict screening of a number of CDMO companies for many reasons. We both think that talent prevails over everything. In recent years, BJ Bioscience has attracted many outstanding returnees and talents with both academic and biopharmaceutical industry experience. CMAB boasts a competent CMC research and manufacturing team covering the entire chain of CMC. CMAB, as a pure-play CDMO company, advocates absolute protection of the intellectual property rights of its customers. Therefore, we believe that our cooperation will accelerate the R&D process of BJ-005. We hope that such collaboration will speed up the development of the innovative therapies of BJ Bioscience to the patients worldwide," said Dr. Haizhou ZHANG, Co-founder and chief executive officer of BJ Bioscience.
"We are extraordinarily delighted and honored to have the opportunity to provide CMC research and manufacturing services to cutting-edge biomedical R&D companies like BJ. CMAB fully understands the most critical needs of innovative drug R&D startups such as BJ. Our objective is to support BJ in attaining another milestone through the quality of IND applications in both China and the United States at the highest speed possible. CMAB will achieve this through our excellent core team, a mature technology integration capability, CDMO services, equipment and facilities of international mainstream brands, and a first-class international GMP quality system," said Dr. Yongzhong WANG, CMAB chief executive officer.
CMAB will provide a full range of CMC research and manufacturing services to support the IND application requirements of both China and the U.S. The collaboration will support the clinical development of BJ-005 worldwide by BJ Bioscience and will leverage CMAB's CMC process development and manufacturing platform, R&D team, and product quality system.
"We had ambitious goals and aspirations at the beginning of setting up BJ Bioscience," said Mr. Xiaoyong, JIN, Chairman of BJ Bioscience. "So far, China's biopharmaceutical companies have very few innovative drugs on the market. We believe that BJ Bioscience will develop real innovative biologics in the foreseeable future. The primary goal for our cooperation with CMAB is that we may focus more on the innovative R&D fields that we are good at and leave the CMC part to CMAB because it is its expertise. We believe that our efforts in all respects will open up an era for stronger, win-win cooperation."
"CMAB stood out in our strict screening of a number of CDMO companies for many reasons. We both think that talent prevails over everything. In recent years, BJ Bioscience has attracted many outstanding returnees and talents with both academic and biopharmaceutical industry experience. CMAB boasts a competent CMC research and manufacturing team covering the entire chain of CMC. CMAB, as a pure-play CDMO company, advocates absolute protection of the intellectual property rights of its customers. Therefore, we believe that our cooperation will accelerate the R&D process of BJ-005. We hope that such collaboration will speed up the development of the innovative therapies of BJ Bioscience to the patients worldwide," said Dr. Haizhou ZHANG, Co-founder and chief executive officer of BJ Bioscience.
"We are extraordinarily delighted and honored to have the opportunity to provide CMC research and manufacturing services to cutting-edge biomedical R&D companies like BJ. CMAB fully understands the most critical needs of innovative drug R&D startups such as BJ. Our objective is to support BJ in attaining another milestone through the quality of IND applications in both China and the United States at the highest speed possible. CMAB will achieve this through our excellent core team, a mature technology integration capability, CDMO services, equipment and facilities of international mainstream brands, and a first-class international GMP quality system," said Dr. Yongzhong WANG, CMAB chief executive officer.
